Latest Biomarker Stories

Investment in a Quebec public-private partnership to support the use of personalized medicine solutions in the treatment of cancer patients

2013-02-15 12:22:47

MONTREAL, Feb. 15, 2013 /PRNewswire/ - The Government of Québec announced today a $10 million investment in the Personalized Medicine Partnership for Cancer (PMPC). This public-private partnership will be focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec and...

Biological Diversity In Triple-negative Breast Cancer Discovered By Researchers

2013-02-14 12:25:02

University of North Carolina Health Care Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity, according to University of North Carolina researchers. In a study published in the February issue of The Oncologist conducted by UNC and the Vall d'Hebron Institute of Oncology in Barcelona, Spain, a team lead by Charles Perou, PhD, of UNC Lineberger Comprehensive Cancer Center, examined more...

Xencor Initiates Phase 1b/2a Trial of XmAb®5871 for Autoimmune Disease

2013-02-13 08:27:48

MONROVIA, Calif., Feb. 13, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in a Phase 1b/2a clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis. XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b (FcgRIIb) pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. The trial initiation triggered a milestone...

PAML Introduces Blood Test to Aid in the Early Detection of Lung Cancer

2013-02-12 23:03:30

Full Service National Reference Laboratory, PAML, leader in its field, introduces blood test to aid in the early detection of lung cancer. (PRWEB) February 12, 2013 PAML (Pathology Associates Medical Laboratories, LLC) announced today that it has entered into an agreement with Oncimmune® USA LLC to offer the EarlyCDT®-Lung test. EarlyCDT-Lung is an innovative blood test that aids in the risk assessment and the early detection of lung cancer. Lung cancer is the leading cause of...

Shiel Medical Laboratory's Oxidized LDL Triple Marker Test Uncovers Symptoms of Latent Heart Disease Better than Standard Lipid Test

2013-02-12 08:31:26

NEW YORK, Feb. 12, 2013 /PRNewswire/ -- The primary clinical laboratory test used by physicians to identify patients with coronary artery disease (CAD) fails to measure oxidized low-density lipoprotein (LDL), the plaque-specific protein directly involved in the disease process. A key study demonstrated that nearly half the patients with documented coronary events had LDL cholesterol readings within healthy range, exposing a major weakness in the standard lipid panel and the need for...

Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel

2013-02-11 08:27:15

EMERYVILLE, Calif., Feb. 11, 2013 /PRNewswire/ -- Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that it has initiated clinical testing in the U.S. to evaluate the Omega-3 Cardiac Panel. The panel quantitatively tests whole blood specimens for levels of cardiac troponin I (cTnI), myoglobin and...

InterMune To Release Fourth Quarter Financial Results On February 21

2013-02-11 08:26:20

BRISBANE, Calif., Feb. 11, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full-year 2012 financial results at the close of the U.S. markets on Thursday, February 21, 2013. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. (Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) Interested investors and others may participate in the conference call by dialing...

Astute Medical To Host Kidney Injury Symposium At CRRT 2013

2013-02-11 04:20:48

SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- Leading critical care experts will discuss new techniques for assessing risk of acute kidney injury (AKI) at an educational symposium to be held at the Eighteenth International Conference on Continuous Renal Replacement Therapies (CRRT) in San Diego. The symposium, "New AKI Biomarkers: A Revolution in Risk Assessment," will be held on Thursday, February 14, 2013, from 12:40 p.m. to 2:00 p.m. local time. Interested participants can visit...

Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers

2013-02-06 04:21:43

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Citing results of a clinical study published today in Critical Care, Astute Medical Chief Executive Officer Chris Hibberd said he is confident about the prospects for newly validated biomarkers of kidney damage used in the Company's NephroCheck(®) Test. The international, multi-center study validated the ability to predict acute kidney injury (AKI) using measurements of the two biomarkers, Insulin-like growth factor-binding protein 7 (IGFBP7)...

Viracor-IBT Laboratories Acquires Assets of Cylex(TM)

2013-02-05 16:23:28

LEE'S SUMMIT, Mo., Feb. 5, 2013 /PRNewswire/ -- Viracor-IBT Laboratories, Inc. announced today that it has signed a definitive agreement to purchase the assets of Cylex(TM), Inc., a global life sciences company focused on the development, manufacturing and commercialization of in vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. This includes the acquisition of Cylex's core product, ImmuKnow®, a noninvasive biomarker of immune function...